{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MDX-010+%28CTLA-4%29&page=7", "query": { "intervention": "MDX-010 (CTLA-4)", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 238, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MDX-010+%28CTLA-4%29&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MDX-010+%28CTLA-4%29&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T12:12:16.729Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acinar Cell Carcinoma", "Adenoid Cystic Carcinoma", "Adrenal Cortical Carcinoma", "Adrenal Gland Pheochromocytoma", "Anal Canal Neuroendocrine Carcinoma", "Anal Canal Undifferentiated Carcinoma", "Angiosarcoma", "Apocrine Neoplasm", "Appendix Mucinous Adenocarcinoma", "Bartholin Gland Transitional Cell Carcinoma", "Basal Cell Carcinoma", "Bladder Adenocarcinoma", "Breast Metaplastic Carcinoma", "Cervical Adenocarcinoma", "Cholangiocarcinoma", "Chordoma", "Colorectal Squamous Cell Carcinoma", "Desmoid Fibromatosis", "Endometrial Transitional Cell Carcinoma", "Endometrioid Adenocarcinoma", "Esophageal Neuroendocrine Carcinoma", "Esophageal Undifferentiated Carcinoma", "Extrahepatic Bile Duct Carcinoma", "Extramammary Paget Disease", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fibromyxoid Tumor", "Gallbladder Carcinoma", "Gastric Neuroendocrine Carcinoma", "Gastric Squamous Cell Carcinoma", "Gastric Undifferentiated Carcinoma", "Gastrointestinal Stromal Tumor", "Gestational Trophoblastic Tumor", "Giant Cell Carcinoma", "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type", "Intestinal Neuroendocrine Carcinoma", "Intrahepatic Cholangiocarcinoma", "Lung Neuroendocrine Tumor", "Lung Sarcomatoid Carcinoma", "Major Salivary Gland Carcinoma", "Malignant Neoplasm of Unknown Primary", "Malignant Odontogenic Neoplasm", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Solid Neoplasm", "Malignant Testicular Sex Cord-Stromal Tumor", "Metastatic Pituitary Neuroendocrine Tumor", "Minimally Invasive Lung Adenocarcinoma", "Mixed Mesodermal (Mullerian) Tumor", "Mucinous Adenocarcinoma", "Mucinous Cystadenocarcinoma", "Nasal Cavity Adenocarcinoma", "Nasal Cavity Carcinoma", "Nasopharyngeal Carcinoma", "Nasopharyngeal Low Grade Papillary Adenocarcinoma", "Nasopharyngeal Undifferentiated Carcinoma", "Oral Cavity Carcinoma", "Oropharyngeal Undifferentiated Carcinoma", "Ovarian Adenocarcinoma", "Ovarian Germ Cell Tumor", "Ovarian Mucinous Adenocarcinoma", "Ovarian Squamous Cell Carcinoma", "Ovarian Transitional Cell Carcinoma", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Neuroendocrine Carcinoma", "Paraganglioma", "Paranasal Sinus Adenocarcinoma", "Paranasal Sinus Carcinoma", "Parathyroid Gland Carcinoma", "PEComa", "Penile Squamous Cell Carcinoma", "Peritoneal Mesothelial Neoplasm", "Placental Choriocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Pseudomyxoma Peritonei", "Rare Disorder", "Scrotal Squamous Cell Carcinoma", "Seminal Vesicle Adenocarcinoma", "Seminoma", "Serous Cystadenocarcinoma", "Small Intestinal Adenocarcinoma", "Small Intestinal Squamous Cell Carcinoma", "Spindle Cell Neoplasm", "Teratoma With Somatic-Type Malignancy", "Testicular Non-Seminomatous Germ Cell Tumor", "Thyroid Gland Carcinoma", "Tracheal Carcinoma", "Transitional Cell Carcinoma", "Ureter Adenocarcinoma", "Ureter Squamous Cell Carcinoma", "Urethral Adenocarcinoma", "Urethral Squamous Cell Carcinoma", "Vaginal Adenocarcinoma", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified", "Vulvar Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 798, "start_date": "2017-01-30", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-15T12:12:16.729Z", "location_count": 1006, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02834013" }, { "nct_id": "NCT07838974", "title": "Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 40, "start_date": "2026-11-01", "completion_date": "2030-11-01", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-15T12:12:16.729Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07838974" }, { "nct_id": "NCT04739618", "title": "Metastatic Solid Cancer Clinical Trial", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer" ], "interventions": [ { "name": "Keytruda Injectable Product", "type": "DRUG" }, { "name": "Yervoy Injectable Product", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "Non-ablative Cryosurgical freezing", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "ImmunSYS, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2021-03-04", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2024-07-23", "last_synced_at": "2026-10-15T12:12:16.729Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Miami Lakes, Florida", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Miami Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04739618" }, { "nct_id": "NCT07075120", "title": "Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "Ipilimumab and Nivolumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Hawaii", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-04-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-15T12:12:16.729Z", "location_count": 2, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT07075120" }, { "nct_id": "NCT03449108", "title": "LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Sarcoma", "Dedifferentiated Chondrosarcoma", "Giant Cell Tumor of Bone", "Malignancy in Giant Cell Tumor of Bone", "Malignant Solid Neoplasm", "Ovarian Carcinosarcoma", "Platinum-Resistant Ovarian Carcinoma", "Poorly Differentiated Thyroid Gland Carcinoma", "Recurrent Osteosarcoma", "Recurrent Ovarian Carcinoma", "Refractory Osteosarcoma", "Soft Tissue Sarcoma", "Thyroid Gland Anaplastic Carcinoma", "Thyroid Gland Squamous Cell Carcinoma", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Autologous Tumor Infiltrating Lymphocytes LN-145", "type": "BIOLOGICAL" }, { "name": "Autologous Tumor Infiltrating Lymphocytes LN-145-S1", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2018-04-27", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-15T12:12:16.729Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03449108" }, { "nct_id": "NCT01711515", "title": "Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Stage IB2 Cervical Cancer AJCC v6 and v7", "Stage II Cervical Cancer AJCC v7", "Stage IIA Cervical Cancer AJCC v7", "Stage IIB Cervical Cancer AJCC v6 and v7", "Stage IIIB Cervical Cancer AJCC v6 and v7", "Stage IVA Cervical Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Internal Radiation Therapy", "type": "RADIATION" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 34, "start_date": "2012-10-01", "completion_date": "2020-07-17", "has_results": false, "last_update_posted_date": "2020-09-02", "last_synced_at": "2026-10-15T12:12:16.729Z", "location_count": 16, "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01711515" }, { "nct_id": "NCT03422094", "title": "Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "NeoVax", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Research blood draw", "type": "PROCEDURE" }, { "name": "Leukapheresis for research", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-10-31", "completion_date": "2020-12-31", "has_results": false, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-10-15T12:12:16.729Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03422094" }, { "nct_id": "NCT01585194", "title": "Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Uveal Melanoma", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2012-11-29", "completion_date": "2024-05-14", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-10-15T12:12:16.729Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585194" }, { "nct_id": "NCT03274258", "title": "Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Medullary Carcinoma", "Loss of INI 1 Protein Expression", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2018-05-29", "completion_date": "2025-11-21", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-15T12:12:16.729Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03274258" }, { "nct_id": "NCT04090775", "title": "A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostatic Adenocarcinoma" ], "interventions": [ { "name": "Opdivo Injectable Product", "type": "DRUG" }, { "name": "Yervoy Injectable Product", "type": "DRUG" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Cryosurgical freezing (cryosurgery)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Rampart Health, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 12, "start_date": "2019-06-28", "completion_date": "2022-01-31", "has_results": false, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-10-15T12:12:16.729Z", "location_count": 2, "location_summary": "Lancaster, California • Rochester, Michigan", "locations": [ { "city": "Lancaster", "state": "California" }, { "city": "Rochester", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04090775" } ] }